Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 287

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 287
---
 would have been issuable if the Alternate Conversion Price had been equal to 80% of the volume weighted average
price of the Common Stock during the five consecutive trading days immediately prior to such conversion.

Other Adjustments.
In connection with the Private Placement, we have agreed to seek stockholder approval at a special meeting of stockholders to be held
not later than December 15, 2024 of the issuance of Conversion Shares at a conversion price below the Conversion Price (the date of such
approval, the “Second Stockholder Approval Date”). If, on or after the Stockholder Approval Date, we issue any shares of
Common Stock for a consideration per share (the “New Issuance Price”) less than a price equal to the Conversion Price in
effect immediately prior to such issuance, the Conversion Price shall be reduced to the New Issuance Price.

If 30 days or 60 days following
the occurrence of the later of (x) the Second Stockholder Approval Date and (y) the earlier of (a) the effective date of the registration
statement to be filed pursuant to the Second Registration Rights Agreement and (b) the date that the Series C Preferred Stock is
eligible to be resold without restriction under Rule 144 of the Securities Act, the Conversion Price then in effect is
greater than the greater of $0.0196 and the Market Price (as defined in the Series C Certificate of Designations) then in effect (the
“Series C Adjustment Price”), the Conversion Price shall automatically lower to the Series C Adjustment Price.

Covenants. The Series
C Certificate of Designations contains a variety of obligations on our part not to engage in specified activities, which are typical
for transactions of this type. In particular, we will not, and will cause our subsidiaries to not, redeem, repurchase or declare any
dividend or distribution on any of our capital stock (other than as required under the Series C Certificate of Designations) and will
not incur any indebtedness other than ordinary course trade payables or, subject to certain exceptions, incur any liens. In addition,
we will not issue any preferred stock or issue any other securities that would cause a breach or default under the Series C Certificate
of Designations. Any waiver or amendment of the foregoing covenants by the Required Holders (as defined in the Series C Certificate of
Designations) shall be deemed to be a waiver or amendment by the Required Holders (as defined in the Series C Certificate of Design